Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma

Satoshi Watanabe, Takashi Sone, Tomoharu Matsui, Kenta Yamamura, Mayuko Tani, Akihito Okazaki, Koji Kurokawa, Yuichi Tambo, Hazuki Takato, Noriyuki Ohkura, Yuko Waseda, Nobuyuki Katayama, Kazuo Kasahara*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

We report the case of a 52-year-old woman with lung adenocarcinoma treated with EGFR tyrosine kinase inhibitor (TKI) therapy. After disease progression, histological examination of a secondary biopsy specimen revealed small-cell lung cancer (SCLC) that was sensitive to standard SCLC treatment. Tumor markers, including ProGRP and NSE, were elevated. Transformation to SCLC is a mechanism for acquired resistance to EGFR-TKI therapy. Secondary biopsy is important for evaluation of genetic and histological changes and selection of appropriate treatment. Furthermore, ProGRP and NSE may be useful for early detection of SCLC transformation in cases resistant to EGFR-TKI therapy.

Original languageEnglish (US)
Pages (from-to)370-372
Number of pages3
JournalLung Cancer
Volume82
Issue number2
DOIs
StatePublished - Nov 2013

Keywords

  • Adenocarcinoma
  • EGFR tyrosine kinase inhibitors
  • NSE
  • ProGRP
  • Resistance
  • Small cell lung cancer
  • Transformation

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this